Pilot studies on intranasal insulin in AD patients and older adults at high dementia risk using the previously mentioned ViaNaseTM for drug delivery, showed sufficient insulin penetration into the brain via CSF analyses [237, 242]. The gene discussed is INS; the disease is Alzheimer disease.